Methods A total of 271 patients with malignant tumors admitted to the hospital from January 2019 to January 2019 were selected and divided into VTE group (51 cases) and non-VTE group (220 cases) according to whether the patients had VTE. Coagulation factors Ⅷ/Ⅸ, fibrinogen, CRP and general data of the two groups were compared, and the risk factors of VTE in patients with malignant tumors were determined by Logistic regression analysis. A VTE risk identification model was constructed according to the influencing factors, and the distinction and fit of the model were verified by receiver operating characteristic curve (ROC) and Hosmer-Lemeshow test.Results Ⅷ level, Ⅸ level, fibrinogen level and CRP level in VTE group were higher than those in non-VTE group (P < 0.05). The prevalence rate of diabetes mellitus, the rate of receiving surgery, the rate of receiving chemotherapy and the score of Khorana risk assessment model ≥ 2 in VTE group were higher than those in non-VTE group (P < 0.05). High coagulation factor Ⅷ/Ⅸ level [O^R =2.721 (95% CI: 2.379, 3.063) ], high fibrinogen level [O^R =2.354 (95% CI: 1.225, 3.482) ], high CRP level [O^R =2.149 (95% CI: 1.354, 2.944) ], chemotherapy [O^R =1.960 (95% CI: 1.754, 3.166) ], Khorana risk assessment model score ≥ 2 points [O^R =2.472 (95% CI: 1.414, 4.321) ] were risk factors for VTE in patients with malignant tumors (P < 0.05). A nomogram model was constructed based on risk factors. The total score was 145 to 425, corresponding to the risk range of 0.1 to 0.9, the higher the score, the greater the risk of VTE. ROC curve was drawn according to the results of VTE risk curve of malignant tumor patients. The results showed that the area under the curve of the model was 0.905 (95% CI: 0.854, 0.942), the sensitivity was 92.68%, the specificity was 83.22%, and the Yoden index was 0.759. Calibration curve shows that the calibration curve of this prediction model is close to the actual curve, (P > 0.05).Conclusion The VTE nomogram model of malignant tumor patients based on coagulation factor Ⅷ/Ⅸ, fibrinogen and CRP has good differentiation and accuracy.Objectiv To explore the effects of coagulation factor Ⅷ/Ⅸ, fibrinogen and C-reactive protein (CRP) on venous thromboembolism (VTE) in patients with malignant tumors, and build a prediction model.